Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01749397

A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Study identifier: NCT01749397
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Metastatic epithelial ovarian, primary peritoneal, or fallopian tube cancer for which standard curative measures do not exist, no prior PARP inhibitor.

Type of study:

Phase I study

Treatment:

21-day cycles with veliparib intravenously on days 1-10 and floxuridine intraperitoneal on days 3-5

Study sites:

Maryland
Baltimore
Johns Hopkins University
Contact: Deborah K. Armstrong 410-955-8804 jhcccro@jhmi.edu
Principal Investigator: Deborah K. Armstrong

Minnesota
Rochester
Mayo Clinic
Contact: Andrea E. Wahner Hendrickson 507-284-2511 wahnerhendrickson.andrea@mayo.edu

Page updated 06/13/13